Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease

Abstract Infliximab is commonly used in inflammatory bowel disease (IBD), however, differences in clinical response among patients are common. Several studies have considered the possibility that these differences are caused by genetic variability even if no unique marker has been yet identified in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Debora Curci, Marianna Lucafò, Adriana Cifù, Martina Fabris, Matteo Bramuzzo, Stefano Martelossi, Raffaella Franca, Giuliana Decorti, Gabriele Stocco
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/e408575cf9204c19966ff15cc6a33963
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!